<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2d3f0cf1-54b1-4b7a-b11b-e3451e2bd180"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Derma-Smoothe/FS<sup>®</sup> safely and effectively. See full prescribing information for Derma-Smoothe/FS<sup>®</sup>.<br/>Derma-Smoothe/FS<sup>®</sup> (fluocinolone acetonide) Topical Oil, 0.01%<br/>(Body Oil)<br/>For Topical Use Only<br/>Not for Oral, Ophthalmic, or Intravaginal Use<br/>NDC 68791-101-04<br/>Initial U.S. Approval: 1988 </title>
   <effectiveTime value="20250424"/>
   <setId root="bc61c619-a71c-46f5-80f1-9e9ee71134aa"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="078374385" root="1.3.6.1.4.1.519.1"/>
            <name>Royal Pharmaceuticals</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c2f39cdd-5126-496c-a2cb-5d871ee67082"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL LISTING DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240607"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68791-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Derma-Smoothe/FS</name>
                        <formCode code="C42965" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OIL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>fluocinolone acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.11" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>fluocinolone acetonide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>fluocinolone acetonide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N6K5787QVP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIGHT MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7L6R1SQ6M0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLETH-2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="118.28" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68791-101-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19950216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68791-101-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240506"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019452" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19950216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="0e24ef3f-6ff7-4f54-865c-899460adcc70"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20131001"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indication and Usage, Pediatric Patients with Atopic Dermatitis (<linkHtml href="#S1.2">1.2</linkHtml>) 11/2007</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="9ff2cacc-d4a1-424b-976c-37928dc7cc1d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> is a corticosteroid indicated for the</paragraph>
                        <list>
                           <item>topical treatment of atopic dermatitis in adult patients (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                        <paragraph>Limitations of Use:</paragraph>
                        <list>
                           <item>Apply the least amount to cover affected areas.<br/>Discontinue when disease is controlled. (<linkHtml href="#S1.3">1.3</linkHtml>) </item>
                           <item>Do not use in the diaper area. (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>Do not use on the face, axillae, or groin. (<linkHtml href="#S1.3">1.3</linkHtml>, <linkHtml href="#S6.2">6.2</linkHtml>, <linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="78e15347-6d09-4f86-83a4-3c0a68328480"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Adult Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> is indicated for the topical treatment of atopic dermatitis in adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="9c0b9c5c-0066-4614-af09-bc9175e68ae9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Pediatric Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. Safety and effectiveness in pediatric patients younger than 3 months of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="5dd4bada-3106-419d-95dc-72748aded685"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Limitations of Use</title>
                     <text>
                        <paragraph>Apply the least amount of Derma-Smoothe/FS<sup>®</sup> needed to cover the affected areas. As with other corticosteroids, Derma-Smoothe/FS<sup>®</sup> should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks.</paragraph>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use.</paragraph>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> should not be used on the face, axillae, or groin unless directed by the physician. Application to intertriginous areas should be avoided due to the increased risk of local adverse reactions. <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml> and <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="bb4c9345-3768-43af-9c78-1419a4482959"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Derma-Smoothe/FS<sup>®</sup> is not for oral, ophthalmic, or intravaginal use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The dosing of Derma-Smoothe/FS<sup>®</sup> is different for adult and pediatric patients.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> is not for oral, ophthalmic, or intravaginal use.(<linkHtml href="#S2">2</linkHtml>)</paragraph>
                        <list>
                           <item>Adult patients: Apply to affected areas 3 times daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Pediatric patients: Moisten skin and apply to affected areas twice daily for up to 4 weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="01fb5d4a-5036-438f-9de2-03f323e2a163"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adult Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Apply Derma-Smoothe/FS<sup>®</sup> as a thin film to the affected areas <content styleCode="underline">three times daily</content>.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="fdea51f9-6e96-4444-ba97-39cfbd69ac3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pediatric Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Moisten skin and apply Derma-Smoothe/FS<sup>®</sup> as a thin film to the affected areas <content styleCode="underline">twice daily for up to four weeks</content>.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="50a7a86c-0fe2-4285-a6d8-03e1e8a73ebc"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Derma-Smoothe/FS<sup>®</sup> (fluocinolone acetonide), Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces.</paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> (fluocinolone acetonide) Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4d15d76c-2e53-4ce0-86b5-11731bfb9a20"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="2d8b8bc2-9adc-4c3c-a374-bef8f6ceefe2"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Topical corticosteroids can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Systemic absorption may require evaluation for hypothalamic-pituitary-adrenal (HPA) axis suppression. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Modify use should HPA axis suppression develop. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Potent corticosteroids use on large areas, prolonged use or occlusive use may increase systemic absorption. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids (<linkHtml href="#S5.2">5.2</linkHtml>,<linkHtml href="#S5.3">5.3</linkHtml>,<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>Children may be more susceptible to systemic toxicity from equivalent doses. (<linkHtml href="#S5.1">5.1</linkHtml>,<linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="5c15b2fd-75c4-4edd-b067-1dfef8ba604f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypothalamic-Pituitary-Adrenal Axis Suppression</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing's syndrome, hyperglycemia, and glucosuria can also be produced by systemic absorption of topical corticosteroids.</paragraph>
                        <paragraph>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.</paragraph>
                        <paragraph>If HPA axis suppression is documented, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids.</paragraph>
                        <paragraph>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, and use of occlusive dressings. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. <content styleCode="italics">[See <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="f7765ed3-e4eb-4be3-a6ae-5e89e12457ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Local Adverse Reactions with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Local adverse reactions may occur with use of topical corticosteroids and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. <content styleCode="italics">[See <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="b7535f31-a93a-408e-985f-e2a55895d9a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Allergic Contact Dermatitis with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a <content styleCode="italics">failure to heal</content> rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="42f846a9-8ea0-49fe-8a4b-5109c8918e79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection persists unchanged, Derma-Smoothe/FS<sup>®</sup> should be discontinued until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="8092baf1-36b2-4cea-bf0f-f559f58cb0fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Use in Peanut-Sensitive Individuals</title>
                     <text>
                        <paragraph>Physicians should use caution in prescribing Derma-Smoothe/FS<sup>®</sup> for peanut-sensitive individuals. <content styleCode="italics">[See <linkHtml href="#S11">Description (11)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, Derma-Smoothe/FS<sup>®</sup> should be discontinued immediately and appropriate therapy instituted.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="4d62c2d1-50ff-4a03-9f09-9d9cbbd1d1fa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥ 5%) were cough (20%), rhinorrhea (13%), pyrexia (10% ), telangiectasia (7%), nasopharyngitis (7%), and hypopigmentation (7%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hill Dermaceuticals, Inc. at 1-800-344-5707 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="b772685e-f91e-4549-9946-8e61b58b9c32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience: Evaluation of Facial Use in Pediatric Subjects</title>
                     <text>
                        <paragraph>An open-label study was conducted in 58 children with moderate to severe atopic dermatitis (2 to 12 years old) to evaluate the safety of Derma-Smoothe/FS<sup>®</sup> when applied to the face twice daily for 4 weeks. The following adverse reactions were reported:</paragraph>
                        <table width="100%">
                           <caption>Incidence of Adverse Reactions (%), N=58</caption>
                           <col width="30%" align="left" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction (AR)<footnote>The number of individual adverse reactions reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse reaction.</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold"># of subjects (%)</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Day 14</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Day 28<footnote>End of Treatment</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Day 56<footnote>Four Weeks Post Treatment</footnote>
                                    </content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Any AE</td>
                                 <td styleCode="Rrule">15 (26)</td>
                                 <td styleCode="Rrule">6 (10)</td>
                                 <td styleCode="Rrule">7 (12)</td>
                                 <td styleCode="Rrule">7 (12)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Telangiectasia</td>
                                 <td styleCode="Rrule">5 (9)</td>
                                 <td styleCode="Rrule">3 (5)</td>
                                 <td styleCode="Rrule">4 (7)</td>
                                 <td styleCode="Rrule">2 (4)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Erythema</td>
                                 <td styleCode="Rrule">3 (5)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Itching</td>
                                 <td styleCode="Rrule">3 (5)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Irritation</td>
                                 <td styleCode="Rrule">3 (5)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Burning</td>
                                 <td styleCode="Rrule">3 (5)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hypopigmentation</td>
                                 <td styleCode="Rrule">2 (4)</td>
                                 <td styleCode="Rrule">2 (4)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Shiny skin</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Secondary atopic dermatitis</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Papules and pustules</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Keratosis pilaris</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Folliculitis</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Facial herpes simplex</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Acneiform eruption</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Ear infection</td>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">1 (2)</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="d11bfe7f-5ca2-41d6-b641-a60de43b6ea7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Clinical Studies Experience: Evaluation in Pediatric Subjects 3 months to 2 years old</title>
                     <text>
                        <paragraph>An open-label safety study was conducted in 29 children to assess the HPA axis by ACTH stimulation testing following use of Derma-Smoothe/FS<sup>®</sup> twice daily for 4 weeks. The following adverse reactions were reported in the study [See <content styleCode="italics">
                              <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>
                           </content>];</paragraph>
                        <table width="80%">
                           <caption>Adverse Reactions (%), N=30<footnote>Includes one subject who withdrew at Week 2</footnote>
                           </caption>
                           <col width="50%" align="left" valign="middle"/>
                           <col width="50%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold"># of subjects (%)</content>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Diarrhea</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Vomiting</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Pyrexia</td>
                                 <td styleCode="Rrule">3 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Abscess</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Molluscum</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                 <td styleCode="Rrule">2 (7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">URI</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Otitis media</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Cough</td>
                                 <td styleCode="Rrule">6 (20)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Rhinorrhea</td>
                                 <td styleCode="Rrule">4 (13)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Atopic dermatitis</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Eczema</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hyperpigmentation</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hypopigmentation</td>
                                 <td styleCode="Rrule">2 (7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Rash</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="64c5690a-bc92-4333-b9cd-cf0cad0503da"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20130701"/>
               <component>
                  <section ID="S8.1">
                     <id root="d99d9104-4a3d-4cf9-a082-4390be833cd9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20130701"/>
                     <component>
                        <section>
                           <id root="a83d8df7-b32c-4ab2-8295-237aa0bd4265"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <text>
                              <paragraph>Pregnancy Category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</paragraph>
                              <paragraph>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Derma-Smoothe/FS<sup>®</sup>. Therefore, Derma-Smoothe/FS<sup>®</sup> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20130701"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="3d83a3ab-fcb5-4c3e-b0f3-ccb1061d4685"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.</paragraph>
                        <paragraph>Because many drugs are excreted in human milk, caution should be exercised when Derma-Smoothe/FS<sup>®</sup> is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="50d27451-a780-490f-9d7f-2ba3683cd485"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <effectiveTime value="20130701"/>
                     <component>
                        <section>
                           <id root="e7dd9e68-de61-4b9b-9f6b-2e4821a4fa41"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">8.4.1 Systemic Adverse Reactions in Pediatric Patients</content>
                              </paragraph>
                              <paragraph>HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                              <paragraph>Because of a higher ratio of skin surface area to body mass, children are at a greater risk for systemic adverse reactions than are adults when treated with topical corticosteroids. <content styleCode="italics">[See <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20130701"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cb55148a-dcc5-483b-b4c0-81b323a543d6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">8.4.2 Evaluation in Peanut-Sensitive Pediatric Subjects</content>
                              </paragraph>
                              <paragraph>A clinical study was conducted to assess the safety of Derma-Smoothe/FS<sup>®</sup>, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 subjects with atopic dermatitis, 6 to 17 years of age. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the subjects' responses to both prick test and patch test utilizing peanut oil NF, Derma-Smoothe/FS<sup>®</sup> and histamine/saline controls. Subjects were also treated with Derma-Smoothe/FS<sup>®</sup> twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to Derma-Smoothe/FS<sup>®</sup> and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of Derma-Smoothe/FS<sup>®</sup>. The bulk peanut oil NF, used in Derma-Smoothe/FS<sup>®</sup> is heated at 475°F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins. <content styleCode="italics">[See <linkHtml href="#S11">Description (11)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20130701"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0ba6e82e-a4a0-4e87-a8c1-adbbc72dc2d4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">8.4.3 Evaluation in Pediatric Subjects 2 to 6 years old</content>
                              </paragraph>
                              <paragraph>Open-label safety studies were conducted on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis. Subjects were treated with Derma-Smoothe/FS<sup>®</sup> twice daily for 4 weeks. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Morning pre-stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol &gt; 7µg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 µg/dL).</paragraph>
                           </text>
                           <effectiveTime value="20130701"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="42736a28-0f8e-49b0-821d-1b8ca8e12c5a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">8.4.4 Evaluation in Pediatric Subjects 3 months to 2 years old</content>
                              </paragraph>
                              <paragraph>An open-label safety study was conducted in 29 children (7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months and 15 subjects ages &gt; 12 months to 2 years of age) to assess the HPA axis by ACTH stimulation testing following use of Derma-Smoothe/FS<sup>®</sup> twice daily for 4 weeks. All subjects had moderate to severe atopic dermatitis with disease involvement on at least 20% body surface area. Baseline body surface area involvement was 50% to 75% in 11 subjects and greater than 75% in 7 subjects. Morning pre-stimulation and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. All subjects had normal responses to 0.125 mg of ACTH stimulation (cortisol &gt; 18 µg/dL).</paragraph>
                           </text>
                           <effectiveTime value="20130701"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="c7f7def8-e351-4f84-900f-6a80c7d4dbf0"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects, including under conditions of normal use. <content styleCode="italics">[See <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20130701"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="567ee104-5b6a-438a-aef3-1d81762f08f9"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Derma-Smoothe/FS<sup>®</sup> (fluocinolone acetonide), Topical Oil, 0.01% (Body Oil) contains fluocinolone acetonide [(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17 [(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use.</paragraph>
                  <paragraph>This formulation is also marketed as Derma-Smoothe/FS<sup>®</sup> (fluocinolone acetonide), Topical Oil, 0.01% (Scalp Oil) for use with shower caps for treatment of scalp psoriasis in adults, and as fluocinolone acetonide oil, 0.01% for treatment of chronic eczematous external otitis. Chemically, fluocinolone acetonide is C<sub>24</sub> H<sub>30</sub> F<sub>2</sub> O<sub>6</sub>. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fluocinolone acetonide in Derma-Smoothe/FS<sup>®</sup> has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.</paragraph>
                  <paragraph>Each gram of Derma-Smoothe/FS<sup>®</sup> contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF and fragrances.</paragraph>
                  <paragraph>Derma-Smoothe/FS<sup>®</sup> is formulated with 48% refined peanut oil NF. The peanut oil used in Derma-Smoothe/FS<sup>®</sup> is tested for peanut proteins through amino acid analysis which can detect the quantity of amino acids to below 0.5 parts per million.</paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="7d77937f-c3a3-49ec-85f0-cbd991c31e66-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="65afa900-3fd9-4881-85ac-26020e0c7038"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20130701"/>
               <component>
                  <section ID="S12.1">
                     <id root="aa9fb5ff-1c92-4f45-ad7f-3d4e466eb86b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="cf4c76d7-8439-4518-9e7e-42e47a4ab9bb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. </paragraph>
                        <paragraph>The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.</paragraph>
                        <paragraph>Derma-Smoothe/FS<sup>®</sup> is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies.</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="4c3422db-b130-4cd2-aef9-2b9d30455222"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20130701"/>
               <component>
                  <section ID="S13.1">
                     <id root="87f0e390-f379-4f30-94f0-5bc19eaaf816"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, mutagenesis, impairment of fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Derma-Smoothe/FS<sup>®</sup>. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Derma-Smoothe/FS<sup>®</sup>. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the <content styleCode="italics">in vitro</content> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the in vivo mouse bone marrow micro nucleus assay, the Chinese hamster micronucleus test, and the <content styleCode="italics">in vitro</content> mouse lymphoma gene mutation assay).</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="c8c19574-d8a1-4e4c-8d42-27918395ea6b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED / STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Derma-Smoothe/FS<sup>®</sup> is supplied in bottles containing 4 fluid ounces. It is labeled as Body Oil (<content styleCode="bold">NDC # 68791-101-04</content>).</paragraph>
               </text>
               <effectiveTime value="20130701"/>
               <component>
                  <section>
                     <id root="98349185-d91c-4cec-a7a0-efe872372842"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Storage: Store at 25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="e75975ce-e665-4c8e-86a3-d8d404eaf880"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20130701"/>
               <component>
                  <section ID="S17.1">
                     <id root="e9a93f02-ebbc-410f-a7b8-36c2814f3528"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Instructions</title>
                     <text>
                        <list>
                           <item>Derma-Smoothe/FS<sup>®</sup> should be used as directed by the physician. It is for external use only. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.</item>
                           <item>Derma-Smoothe/FS<sup>®</sup> should not be used for any disorder other than that for which it was prescribed.</item>
                           <item>Patients should report any worsening of their skin condition to their physician promptly.</item>
                           <item>Derma-Smoothe/FS<sup>®</sup> should not be applied under occlusion unless directed by the physician. Derma-Smoothe/FS<sup>®</sup> should not be applied to the diaper area as diapers or plastic pants may constitute occlusive use.</item>
                           <item>Derma-Smoothe/FS<sup>®</sup> should not be used on the face, axillae, or groin unless directed by the physician.</item>
                           <item>As with other corticosteroids, therapy should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks.</item>
                           <item>Do not use other corticosteroid-containing products while using Derma-Smoothe/FS<sup>®</sup> without first consulting your physician.</item>
                        </list>
                     </text>
                     <effectiveTime value="20130701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="dbfcef7a-edbf-48b2-bf11-3fd5e95e75c3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>Hill Dermaceuticals, Inc.<sup>®</sup>
                     <br/>Sanford, FL 32773<br/>1.800.344.5707</paragraph>
                  <paragraph>For: Royal Pharmaceuticals, Inc<br/>Manasquan, NJ 08736<br/>1.800.510.3401</paragraph>
                  <paragraph>Rev. CODE 171A240-1 <br/>Date: 10/2013</paragraph>
               </text>
               <effectiveTime value="20180416"/>
            </section>
         </component>
         <component>
            <section ID="L0d285283-742c-432f-af6c-54ff1c490399">
               <id root="81d96f1c-ea8e-4df1-a326-4808d0c4e1f2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content>
                     <content styleCode="bold">​Principal Display Panel</content>
                  </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">​PRINCIPAL DISPLAY PANEL - 118.28 mL Carton Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 58791-101-04</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Derma-Smoothe/FS<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Fluocinolone Acetonide</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​0.01% Topical Oil</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​(Body Oil)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​FOR TOPICAL USE ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​NOT FOR ORAL, OPHTHALMIC,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​or INTRAVAGINAL USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​SHAKE WELL BEFORE USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​Net Contents 118.28 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​(4 fl. oz.)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​ROYAL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">​PHARMACEUTICALS<sup>​®</sup>​</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L5436c897-2ebc-403b-8154-5b9202a83f7f"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 20 mL Carton Physcian Sample Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOT FOR SALE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHYSICIAN SAMPLE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 68791-101-01</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Derma-Smoothe/FS<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Fluocinolone Acetonide 0.01% Topical Oil</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(BODY OIL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL USE ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOT FOR ORAL OPHTHALMIC,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">OR INTRAVAGINAL USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SHAKE WELL BEFORE USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NET Contents: 20 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Royal Pharmaceuticals<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L7e027c68-3d9a-4801-8ba4-6590548c1f67"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="L5436c897-2ebc-403b-8154-5b9202a83f7f">
                     <text>118 mL bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="derma-smooth-body-oil.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L7e027c68-3d9a-4801-8ba4-6590548c1f67">
                     <text>Physician Sample bottle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sample carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>